Allogeneic murine melanoma cell vaccine: A model for the development of human allogeneic cancer vaccine

Melanoma Research

Volumn 6, Issue 4, 1996, Pages 299-306

  Knight, B C ^a   Souberbielle, B E ^a   Rizzardi, G P ^a   Ball, S E ^a   Dalgleish, A G ^a  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Allogeneic vaccination; Cancer vaccine; Murine melanoma

Indexed keywords

CANCER VACCINE;

ANIMAL CELL; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; MELANOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; VACCINATION;

EID: 0029809018     PISSN: 09608931     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008390-199608000-00004     Document Type: Article

References (33)

1. Pardoll DM. Cancer vaccines. Immunol Today 1993; 14: 310-316.
2. Colombo MP, Forni G. Cytokine gene transfer in tumor inhibition and tumor therapy: where are we now? Immunol Today 1994; 15: 48-51.
3. Dalgleish AG. Cancer vaccines. Eur J Cancer 1994; 30: 1029-1035.
4. Boon T, Cerottini JC, Van den Eynde B, et al. Tumor antigens recognized by T lymphocytes. Annu Rev Immunol 1994; 12: 337-365.
5. Kawakami Y, Zakut R, Topalian SL, et al. Shared human melanoma antigens: recognition by tumour-infiltrating lymphocytes in HLA-A2.1 transfected melanomas. J Immunol 1992; 48: 638-643.
6. Fenton RT, Sznol M, Luster DG, et al. A phase I trial of B7-transfected or parental lethally irradiated allogeneic melanoma cell lines to induce cell-mediated immunity against tumor-associated antigen presented by HLA-A2 or HLA-A1 in patients with stage IV melanoma. Hum Gene Ther 1995; 6: 87-106.
7. Cascinelli N, Foà R, Parmiani G et al. Active immunization of metastatic melanoma patients with interleukin-4 transduced, allogeneic melanoma cells. A phase I-II study. Hum Gene Ther 1994; 5: 1059-1064.
8. Hedley DW, McElwain TC, Currie GA. Specific active immunotherapy does not prolong survival in surgically treated patients with stage IIB malignant melanoma and may promote early recurrence. Br J Cancer 1978; 37: 491-496.
9. Morion DL, Foshag LJ, Hoon DS, et al. Prolongation of survival in metastatic melanoma after active specific immunotherapy with a new polyvalent melanoma vaccine. Ann Surg 1992; 216: 463-482.
10. Doré JF, Portoukalian J, Berthier-Vergnès O, et al. Réponses de malades atteints de mélanome à l'immunisation par oncolysates de mélanomes au virus de la vaccine. Bull Cancer 1990; 77: 881-891.
11. Fidler IJ, Kripke ML. Metastasis results from preexisting variant cells within a malignant tumor Science 1977; 197: 893-895.
12. Fidler IJ, Gruys E, Cifone MA, et al. Demonstration of multiple phenotypic diversity in a murine melanoma of recent origin. JNCI 1981; 67: 947-956.
13. Cloudman AM. Spontaneous neoplasms in mice. In: Snell GD ed. Biology of the Laboratory Mouse. Philadelphia: Blakiston Press, 1941: 168-233.
14. Ziang YZ, Kanfer EJ, MacDonald D, et al. Graft-versus-leukemia following allogeneic bone marrow transplantation: emergence of cytotoxic T lymphocytes reacting to host leukemia cells. Bone Marrow Transplant 1991; 8: 253-258.
15. Eisenthal A, Skormick Y, Merimsky O, et al. Effect of allogeneic tumour cells, interleukin-2 and interleukin-6, on the growth of subcutaneous syngeneic tumours. Cancer Immunol Immunother 1993; 37: 233-239.
16. Hara I, Nguyen H, Takechi Y, et al. Rejection of mouse melanoma elicited by local secretion of interleukin-2: implicating macrophages without T cells or natural killer cells in tumour rejection. Int J Cancer 1995; 61: 253-260.
17. Sredni B, Schwartz RH. Alloreactivity of an antigen-specific T-cell clone. Nature 1980; 287: 855-857.
18. Matis LA, Sorger SB, McElligott DL, et al. The molecular basis of alloreactivity in antigen-specific, major histocompatibility complex-restricted T cell clones. Cell 1987; 51: 59-69.
19. Sherman LA, Chattopadhyay S. The molecular basis of allorecognition. Annu Rev Immunol 1993; 11: 385-402.
20. Huang AY, Golumbek P, Ahmadzadeh M, et al. Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens. Science 1994; 264: 961-965.
21. Hearing VJ, Vieira WD, Law LW. Malignant melanoma: cross reacting (common) tumor rejection antigens. Int J Cancer 1985; 35: 403-409.
22. Gersten DM, Hearing VJ. Antigens of murine melanoma and their cross-species reactivity. Pathobiology 1992; 60: 49-56.
23. Law LW, Vieira WD, Kameyama K, et al. A unique tumor rejection antigen from the S91 murine malignant melanoma. Cancer Res 1987; 47: 5841-5845.
24. Nishi Y, Hosokawa T, Aoike A, et al. Characterisation of effector cells against B16 melanoma in mice inoculated with allogeneic spleen cells. Microbiol Immunol 1994; 38: 217-223.
25. Paciucci PA, Macphail S, Zarling JM, et al. Lysis of syngeneic solid tumours by alloantigen stimulated mouse T and non-T cells. J Immunol 1980; 124: 370-5.
26. Balsari A, Fossati G, Taramelli D, et al. Allostimulation of patients' lymphocytes generates both T and NK-like cells cytotoxic for autologous melanoma. Br J Cancer 1985; 52: 73-80.
27. Feldman M, Eisenthal L. MHC class I genes controlling the metastatic phenotype of tumour cells. Semin Cancer Biol 1991; 2: 337-346.
28. Tanaka K, Gorelik E, Watanabe M, et al. Rejection of B16 melanoma induced by expression of a transfected major histocompatibility complex class I gene. Mol Cell Biol. 1988; 8: 1857-1861.
29. d). Cancer Res 1987; 47: 3136-3140.
30. Hui K, Sim T, Foo TT, et al. Tumor rejection mediated by transfection with allogeneic class I histocompatability gene. J Immunol 1989; 143: 3835-43.
31. Kim TS, Russell SJ, Collins MK, et al. Immunity to B16 melanoma in mice immunized with IL-2 secreting allogeneic mouse fibroblasts expressing melanoma-associated antigens. Int J Cancer 1992; 51: 283-289.
32. Kim TS, Russell SJ, Collins MK, et al. Immunization with interleukin-2-secreting allogeneic mouse fibroblasts expressing melanoma-associated antigens prolongs the survival of mice with melanoma. Int J Cancer 1993; 55: 865-872.
33. Dranoff G, Jaffee E, Lazenby A, et al. Vaccination with irradiated tumor cells engineered to secrete murine granulogyte-macrophage colony-stimulating factor stimulates potent, specific and long-lasting anti-tumor immunity. Proc Natl Acad Sci USA 1993; 90: 3539-3543.